Prostatic Acid Phosphatase: Clinical Utility in D etection, Assessment, and Monitoring Carcinoma of the Prostate*
|
|
- Kory Newton
- 5 years ago
- Views:
Transcription
1 ANNALS O F CLINICAL AND LABORATORY SC IEN C E, Vol. 14, No. 4 Copyright 1984, Institute for Clinical Science, Inc. Prostatic Acid Phosphatase: Clinical Utility in D etection, Assessment, and Monitoring Carcinoma of the Prostate* ALEX A. PAPPAS, M.D. an d RICHARD H. GADSDEN, S r., Ph.D. Departm ent o f Laboratory Medicine, Medical University o f South Carolina, Charleston, SC ABSTRACT Prostatic carcinoma is a significant cause of male cancer death. The majority of cases present as incurable disease. The measurement of acid phosphatase has served to confirm clinically suspected disease and staging. The immunochemical methods have increased clinical sensitivity and specificity in detecting curable occult or confined disease, but not significantly so as to warrant mass screening. Prostatic acid phosphatase remains a test for confirming clinical staging of prostatic carcinoma and a response factor to therapy at present. Introduction Prostatic carcinoma is the third most common malignancy in males. It is the second most common cause of cancer death in males over the age of 55. In 1983 there will be an estimated 73,000 new cases and 23,000 prostatic cancer deaths.35 Prostatic carcinom a is frequently called the pathologist s carcinoma in that it is often found as an occult malignancy at autopsy or in the course of a routine transurethral prostatectom y (TURP). This incidence of occult carcinoma is in direct proportion to the age of the patient at this demise and to the thoroughness for which the malignancy is searched at autopsy. The autopsy incidence increases from approximately 10 percent at age 50 * Address requests for reprints to Richard H. Gadsden, Sr., Ph.D. to approximately 40 percent at age 80 or at a rate of one percent per year.2,22,33 The actual clinical incidence is much less; it is 0.2 percent at age 50, increasing to 0.8 percent at age Thus, it appears there might be two different types of prostatic carcinoma: one of very low m alignant potential which may never manifest itself clinically and one which early on fulfills the biologic and clinical criteria of malignancy.39 Discussion Prostatic carcinoma is most often an adenocarcinoma arising in the acinus of the gland, usually being multifocal or extensive in most cases. The carcinom a tends to be in the periphery of the gland in contrast to benign prostatic hyperplasia (BPH) which tends to localize to the periurethral center of the gland.3,7, /84/ $01.20 Institute for Clinical Science, Inc.
2 2 8 6 PAPPAS AND GADSDEN Prostatic carcinom a is a malignancy which is hormonally dependent upon the action of androgens, primarily dihydrotestosterone, but the hormones are not considered to play a primary role in the pathogenesis of the malignancy.13 Benign prostatic hyperplasia, although hormonally dependent, does not predispose towards malignancy.22 Various clinical staging classifications are presently used which may or may not be comparable (table I). The American Urological Society (AUS) has defined four clinical stages which have been subsequently subdivided. Stage A is occult malignancy and stage B is localized within the prostatic capsule. Both stage A and stage B malignancies are potentially curable.24 Unfortunately, intracapsular malignancy presents clinically in less than 20 to 25 percent of cases. Most prostatic carcinomas present as locally invasive Stage C or as metastic stage D disease. The overall survival is inversely correlated with the extent of the disease (table II). The clinical symptoms of advanced disease, stages C and D, may be urinary obstruction, bone pain, and/or a hard nodular prostate on rectal examination. These findings are present in over 50 percent of cases. The five to 10 year survival has been correlated with T ABLE I Comparison of the Various Clinical Staging Classifications for Prostatic Carcinoma W h itm o r e 39 V a c u r g * 37 Al/Sf29 A J C l /U I C C t2 ^ B 1 B2 T 1N0M 0 T2No M q C l t 3 n 0 m0 c 2 D1 D2 t 4n0m0 t -4» -3 m0 t 1-4 n 1-3 m1 Veterans A d m in is tr a tio n C o o p e r a tiv e G roup. fa m eric a n U r o l o g i c a l S y stem. ^A m erican J o i n t C o m m is s io n /I n te r n a tio n a l U nion A g a in s t C a n c e r. T = tu m o r; N - n o d e s ; M = m e t a s t a s i s the clinical stages. The best survival is with intracapsular disease and the worst obviously with metastatic disease. In initial staging, lymphatic metastases may have occurred and may not be recognized clinically. This would then reclassify initial intracapsular stage A or B or extracapsular C to a metastatic stage D category. The frequency of lymphatic metastases and initial staging appears to correlate even b e tte r w ith the overall survival (table III). The clinical stage of prostatic carcinom a dictates the therapy.30 Beginning with the original reports by the Gutmans,19 serum acid phosphatase (ACP), in fact, the first described tumor marker, has been a valuable adjunct in the diagnosis and management of prostatic carcinoma.15 It became readily apparent with clinical experience that ACP determinations are neither entirely sensitive in detecting early prostatic carcinoma nor specific for prostatic carcinoma.8,21,41 There has been an evolution in the various methods for the analysis of ACP in regards to analytical specificity and sensitivity of the prostatic fraction of ACP culminating with the present immunoassays. The acid phosphatases are a group of phosphohydrolases which hydrolyze phosphoric monoesters in an acidic medium. In prostatic epithelium, the major role of ACP is not known. In prostatic fluid, these ACPs are concerned with metabolic activity of spermatozoa by catalyzing the transfer of phosphates. In the normal prostatic epithelium, there is an orderly process of secretory product synthesis. In BPH and with carcinoma, there is a decrease in the amount of PAP secreted p er cell but an increase in overall PAP production because of the overall increase in cellular mass.34 Various isoenzym es of serum acid phosphatase have been identified. These isoenzymes have been conveniently classified as to being tartrate sensitive (the
3 CARCINOMA OF THE PROSTATE TABLE I I Staging of Prostatic Carcinoma Clinical Incidence/Prevalence/Survival6 '20'38 Clinical Estimated Adjusted Clinical Incidence Prevalence Survival* Stage Physical Findings Percent Percent Percent a i Negative rectal focal tumor *2 Negative rectal diffuse tumor B1 Nodule <1.5 cm or <1 lobe (diffuse) b2 Nodule >1.5 cm or >1 lobe (diffuse) C1 No involvement of seminal vescicles <70g C2 Involvement of seminal vescicles >70g»! Pelvic lymph node involvement or urethral obstruction d 2 Distant lymph node or bone involvement *Five to ten years. prostatic fraction, PAP) or tartrate resistant (the non-prostatic fraction). The tartrate sensitive fraction, which is supposedly specific for the prostatic fraction of total acid phosphatase, is also found in leukocytes, platelets, and other tissues. Normally the prostatic fraction constitutes only 10 to 25 percent of the total serum acid phosphatase found in males, while the platelet fraction constitutes the majority of the remaining fraction.26,41 Elevations of PAP in patients with prostatic carcinoma are due to an actual increase in tum or mass, loss of ductal connections, tissue necrosis, and neovascularization with subsequent leakage of the enzyme into the circulation. Regional lymphatic spread and distant metastases may establish independent sites of enzyme secreting tumor. Parenthetically, nonelevations of PAP may be explained TABLE III Clinical Stage of Prostatic Carcinoma-Incidence of Lymph Node Metastasis and Survival &'29'38 Clinical Stage Frequency of Lymph Node Metastasis Percent Survival Percent 5 95 A1 a B b ci/c D1/D by poorly differentiated m alignancies which have little activity, nondetection by the analytical method used, potential inactivation of the enzyme, tumor barrier, or concomitant hormonal, radiation or chemotherapy ,33,40 With the potential of increased sensitivity and specificity using radioimmunoassay (RIA), the probability of detecting (screening) intracapsular prostatic carcinoma became a potential reality.12 However, this initial enthusiasm has waned considerably.10 In comparing the clinical sensitivity (positive test (p)/presence of disease (d)) of PAP in detecting non-invasive prostatic carcinoma, there is a wide range of sensitivities ranging from 12 to 33 percent in occult stage A disease and eight to 79 percent in intracapsular stage B disease (table IV). There appears to be a general increase in sensitivity as the extent (stage) of disease increases. Stages C and D disease, however, are quite often evident clinically by either rectal exam or by a suspicious history. Measurements of PAP in stages C and D disease are usually only confirmatory of the disease and are usually indicative of the probable extent of the disease. The overall sensitivity of PAP determination by radioimmunoassay for all stages is approximately 50 percent. The various nonisotopic immunoassays appear to have comparable clinical sensitiv
4 288 PAPPAS AND GADSDEN TABLE IV Clinical Sensitivity in Detecting Prostatic Carcinoma by Clinical Stage Percentage Positive (%)-Positive Test/Presence of Disease (P/D) Quinones^2 Mahan28 B r u c e 5 Griffiths G r i f f i t h s F o t i 12 Cumulative Clinical Sensitivity Stage %- (P/D) %- (P/D) %-(P/D) %-(P/D) % (P/D) %- (P/D) % (P/D) A ( 1 / 4 ) ( 2 /1 6 ) ( 4 /3 2 ) ( 7 /5 8 ) ( 4 /2 5 ) ( 8 /2 4 ) 1 6 -( 2 6 /1 5 9 ) B 8 - ( 1 / 1 2 ) ( 9 /1 6 ) ( 1 1 /3 8 ) ( 1 3 /4 1 ) ( 1 0 /2 5 ) ( 2 6 /3 3 ) 4 2 -( 7 0 /1 6 5 ) C ( 6 /1 3 ) ( 6 /2 0 ) ( 3 / 1 4 ) ( 1 7 /3 6 ) ( 1 1 /2 5 ) ( 2 2 /3 1 ) 4 7 -( 6 5 /1 3 9 ) D 5 2 -( 1 4 /2 7 ) ( 2 0 /3 2 ) ( 3 6 /4 1 ) ( 6 2 /7 2 ) 7 6 -( 1 9 /2 5 ) ( 2 3 /2 5 ) 7 8 -(1 7 4 /2 2 2 ) 4 9 -(3 3 5 /6 8 5 ) ities in detecting prostatic carcinoma at the various stages of the disease (table V). However, the enzyme immunoassay (EIA) method described by Davies and Griffiths11 (table V) shows lack of sensitivity at clinical stages C and D. The immunoassay portion of the assay is designed to isolate PAP from the serum milieu with measurement being of PAP activity. As previously pointed out, PAP activity m easurem ents lack the sensitivity as currently demonstrated by the immunoassay (mass measurements). It is now evident that the use of PAP in screening the asymptomatic patient is not warranted because of the relatively low sensitivity in detecting stage A, or even stage B disease, when coupled with the relatively low prevalence of prostatic carcinoma. Even the screening of higher risk groups older men and negroes does not increase the predictive value of a positive test.13 It has been suggested that baseline levels may be drawn on an individual patient and subsequently followed periodically. Although the decision level may not be reached, any upward change from the baseline value may be significant for the individual patient.17 In BPH, elevations of PAP are observed in the various immunoassays: RIA, 10 percent; enzyme linked immunosorbent assay (ELISA), 30 percent; and EIA, six percent. Possible etiologies for the observed PAP elevations in this benign process are: prostatic manipulation, cytolysis of acinar cells, cellular hyperplasia with a concomitant overall increase in enzyme secretion or indeed an occult malignancy which has not been clinically detected (table VI). It is interesting that elevations of PAP TABLE V Clinical Sensitivity Nonisotipic PAP Immunoassays in Detecting Prostatic Carcinoma by Clinical Stage Percent Positive (%)-Positive Test/Presence of Disease (P/D) Griffiths Cooper^ Davies 11 Lee Griffiths18 Cumulative Clinical ELISA (1982) ELISA (1981) EIA (1982) FIA (1980) FIA (1982) Sensitivity Stage %~(P/D) %-(P/D) %- (P/D) %- (P/D) %- (P/D) %-(P/D) A ( 5 / 2 5 ) ( 1 1 / 3 2 ) * ( 7 / 3 1 ) * ( 1 1 /1 5 ) ( 6 / 2 5 ) ( 4 1 / ) B ( 1 1 / 2 5 ) ( 2 4 / 4 3 ) ( 1 1 / 2 5 ) ( 4 6 / 9 3 ) C ( 1 3 / 2 5 ) ( 2 0 / 3 5 ) ( 1 0 / 2 3 ) ( 3 1 / 3 8 ) ( 1 3 / 2 5 ) ( 8 7 / ) D ( 2 1 / 2 5 ) ( 4 7 /5 1 ) ( 2 6 / 5 8 ) ( 3 2 /3 7 ) ( 2 1 / 2 5 ) ( /1 9 6 ) ( /5 6 3 ) ELISA - E nzym e L in k e d I m m u n o s o rb e n t A s s a y. EIA = Enzyme Immuno A ssa y. F IA = F lu o ro im m u n o a s s a y. * C om b ined s t a g e s A & B.
5 CARCINOMA OF THE PROSTATE TABLE VI Prostatic Acid Phosphatase (PAP)-Elevations in Benign Prostatic Hypertrophy (BPH) Percent Elevations-(Number Positive Tests/Total Number Patients) (P/D) %- (P/D) %-(P/D) Quinones32 G r i f f i t h s * 6 Griffiths17 6-(2/36) 9-(2/22) 9-(19/213) 20-(17/84) 9-(6/68) Cooper3 40-(22/56) Davies1 20-(17/84) 6-(4/68) Cumulative 10-(46/423) 31-(39/140) 12-(89/731) Elevation by all immunochemical methods in BPH 6-(4/68) RIA = Radioimmunoassay. ELISA = Enzyme Linked Immunosorbent Assay. EIA = Enzyme Immunoassay. occur in eight percent (33/406) of nonprostatic m alignancies. Overall, these malignancies are of a potentially secretory type: neuroendocrine, carcinoids, oat cell carcinom as, or hem atopoietic malignancies. It is possible that these tumors elaborate one of several substances that are quite immunologically similar to PAP (table VII). Prostatic acid phosphatase is one of several defined response criteria in monitoring patients with prostatic carcinoma. TABLE VII Serum PAP E le v a tio n i n N o n -P ro s ta tic M alig n an cies P e rc e n t E le v a tio n s -(N o. E le v a tio n s /T o ta l No. T ested ) F o t i 12 11% (9/83) Unknown (5) Pulm onary (4) Q uinones32 4% (2/51) Lynphoma (2) G r i f f i t h s 16 9% (10/109) Oat C e ll Carcinom a (4) C arcinoid (2) R enal C e ll Carcinom a (1) A denocarcinom a - Lung (1) A denocarcinom a -. B r e a s t (1) A denocarcinom a - P a n c reas (1) D avies11 8% (3/36) O at C e ll Carcinom a (1) Lymphoma (1) M u ltip le Myeloma (1) Cum ulative 9% (24/279) ELISA - EIA C ooper9 40% (3/80) B ladder Carcinoma (3) D avies11 8% (3/36) O at C e ll Carcinom a (1) Lymphoma (1) Pulm onary Carcinom a (1) Cum ulative 5% (6/116) 8% (30/395) - E le v a tio n by a l l immunochemical methods i n n o n p ro s ta tic m alig n an cy. RIA = R adioim m unoassay. ELISA = Enzyme L inked Im m unosorbent A ssay. EIA = Enzyme Immunoassay. Generally, normalization of a previously elevated value correlates well with response to therapy.25 However, it is important to observe several sequential levels of PAP before determining the response to therapy, i.e., there may be a random or even diurnal fluctuation in isolated determ inations.4 Patients who have a normalization of PAP generally tend to survive longer than patients who continue to have elevations even after rather intensive therapy.31 Summary The newer immunochemical methods are more analytically sensitive and specific. The sensitivity in detecting clinically occult and curable disease has increased, but not significantly enough to warrant using PAP as a screening procedure. The rectal exam remains still the most effective screening procedure. The increased analytical sensitivity has resulted in observed elevations of PAP in the presence of clinically evident BPH. An elevated PAP with a negative rectal exam and prostatic biopsy places the physician in a dilemma as to resolving whether or not occult malignancy indeed exists. This question of false positive PAP is yet to be resolved clinically. The presence of PAP elevation is non-pros
6 2 9 0 PAPPAS AND GADSDEN tatic malignancies is of interest and generally indicates a secretory type of malignancy which is elaborating a protein similar in antigenic qualities as PAP. Prostatic acid phosphatase remains a response factor in monitoring the progression or regression of clinical disease and confirmation of initial clinical disease. References 1. American Joint Committee for Cancer Staging and End Results Reporting. (Committee: O. H. Beahrs, D. T. Carr and P. Rubin). Manual for Staging Cancer Chicago, Whiting Press, 1978, pp B a r o n, E. and A ngrist, A.: Incidence of occult adenocarcinoma of the prostate after 50 years of age. Arch. Path. 32: , B l e n n e r h a s s e t, J. B. and V i c k e r y, A. L.: Carcinoma of the prostate gland. Cancer 19: , B r e c k m a n,w. D., L a s t i n g e r,l. B., and S e d o r, F.: Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. J. Am. Med. Assoc. 245: , B r u c e, A. W., M a h a n, D. E., S u l l i v a n, L. D., and G o l d e n b e r g, L.: The significance of prostatic acid phosphatase in adenocarcinoma of the prostate. J. Urol. 725: , C a t a l o n a, W. J. and Sc o t t, W. W.: Carcinoma of the prostate: A review. J. Urol. JJ9:l-8, C o f f e y, D. S. and Is a a c s,j. T.: Control of prostate growth. Urology (Suppl.) 17:17-24, C o o k, W. B., F i s h m a n, W. H., and C l a r k, B. G.: Serum acid phosphatase of prostatic origin in the diagnosis of prostatic cancer: clinical evaluation of 2408 tests by the Fishman-Lerner Method. J. Urol. 88: , C o o p e r, E. H., G l a s h a n, R., R o b i n s o n, M. R. G., M o r g a n, D. B., and T r a u t n e r, K.: The evaluation of a new enzyme immunoassay for the measurement of prostatic acid phosphatase. Clin. Chim. Acta 113:27-34, C o o p e r, J. F. : The radioimmunochemical measurement of prostatic acid phosphatase: current state of the art. Urol. Clin. N. Am. 7: , D avies,s. N. and G riffiths,j. C.: Prostate specific acid phosphatase: further studies with immunological techniques. Clin. Chim. Acta 122:29-38, F oti,a. G., C o o p e r,j. F., H e r s c h m a n, H., and M a l v a e z,r. R.: Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. New Eng. J. Med. 297: , F ra nk s, L. M.: Etiology, epidemiology, and pathology of prostatic cancer. Cancer 32: , G ittes, R.: Acid phosphatase reappraised, New Engl. J. Med. 297: , G i t t e s, R. F.,and C h u, T. M.: Detection and diagnosis of prostate cancer, Seminars in Oncology. 3: , G r i f f i t h s, J. C.: Prostate-specific acid phosphatase: re-evaluation of radioimmunoassay in diagnosing prostatic disease. Clin. Chem. 26: , G r i f f i t h s, J., R i p p e, D. F., and P a n f i l i, P. R.: Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease. Clin. Chem. 28: , G r i f f i t h s, J. : Clinical applications of fluoroimmunoassay: An evaluation in the diagnosis of early prostate adenocarcinoma. XI International Congress of Clinical Chemistry. Kaiser, E., Gabi, F., Muller, M. M., and Bayer, M., eds. New York, Walter de Gruytel & Co., 1982, pp G u t m a n, A. B. and G u t m a n, E. B.: An acid phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest. 17: , H a n a s h, K. A., U t z, D. C., C o o k, E. N., T a y l o r, W. F., and T it u s, J. L.: Carcinoma of the prostate: a 15-year followup. J. U r o l. 107: , H e r b e r t, F. K.: The estimation of prostatic phosphatase in serum and its use in the diagnosis of prostatic carcinoma. Q. J. Med. 15: , H u t c h i n s o n, G. B.: Epidemiology of prostatic cancer. Semin. Oncology, 3: , International Union Against Cancer (UICC): Classification of Malignant Tumors, 3rd ed. Geneva, 1978, pp J e w e t t, H. J.: The present status of radical prostatectomy for stages A & B prostatic cancer. Urol. Clin. N. Am. 2: , J o h n s o n, D. E. S., S c o t t, W. W., G i b b o n s, R. P., P r o u t, G. R., S c h m i d t, J. D., and M u r p h y, G. P.: Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8: , Lam, L. W., Li, C. Y., Yam, L. T., Smith R. S., and H a c k e r, B.: Comparison of prostatic and nonprostatic acid phosphatase in prostatic acid phosphatase measurement: Its role in detection and management of prostatic cancer. Ann. N.Y. Acad. Sei. 390:1-15, L e e, C. L., C h u, T. M., W a y s m a n, C. Z., S l a c k, H. H., and M u r p h y, G. P.: Value of a new fluorescent immunoassay for human prostatic acid phosphatase in prostatic cancer. Urology i5: , M a h a n, D. E. and D o c t o r, B. P.: A radioimmune assay for human prostatic acid phosphatase levels in prostatic disease. Clin. Biochem. 12:10-17, M u r p h y, G. P., G a e t a, J. F., P i c k e n s, J., and W a j s m a n, Z.: Current status of classification and staging of prostate cancer. Cancer 45: , M u r p h y, G. P. : Prostatic cancer: continuing process. C A 3i:96 110, 1981.
7 3 1. P a u l s o n, D. F., B e r r y, W. R., C o x, E. B., W a l k e r, A., and L a s z l o, J.: Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J. Natl. Can. Inst. 63: , Q u i n o n e s, G. R., R o h n e r, T. J., D r a c o, J. R., and D e m e r s, L. M.: Will prostatic acid phosphatase determination by radioimmunoassay increase the diagnosis of early prostatic cancer? J. Urol, 225: , S c o t t, R., Jr., M u t c h n i k, D. L., L a s k o w s k i, T. Z., and S c h m a l h o r s t, W. R.: Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J. Urol. 101: , S o d e m a n, T. M. and B a t s a k is, J. G.: Acid Phosphatase. Urologic Pathology: The Prostate. Myron Tannenbaum, M., ed. Philadelphia, Lea & Febiger, 1977, pp S i l v e r b e r g E. and L u b e r a, J. A.: A review of CARCINOMA OF THE PROSTATE American Cancer Society estimates of cancer cases and deaths. CA 33:2-25, Urz, D. C. and F a r r o w, G. M.: Pathological differentiation and prognosis of prostatic carcinoma. J. Am. Med. Assoc. 209: , The Veterans Administration Co-operative Urological Research Group: Carcinoma of the prostate: A continuing co-operative study. J. Urol. 92: , The Veterans Administration Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg. Gynec. Obstet. 224:1011:1017, W h i t m o r e, W. F., Jr.: Hormone therapy in prostatic cancer. Am. J. Med. 22: , W o o d w a r d, H. Q.: The clinical significance of serum acid phosphatase. Am. J. Med. 27: , Y a m, L. T.: Clinical significance of the human acid phosphatase a review. Am. J. Med. 56: , 1974.
Definition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationAzad Mohammed Kamal Elden. Evaluation of Acid and Alkaline Phosphates in Benign Prostatic Hyperplasia and. Patients.
Evaluation of Acid and Alkaline Phosphates in Benign Prostatic Hyperplasia and Prostatic Cancer Azad Mohammed Kamal Elden Abstract Tumors of prostate are common diseases that afflict the aging male population
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationEnzyme Tests in Diseases of the Prostate
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 7, No. 3 Copyright 1977, Institute for Clinical Science Enzyme Tests in Diseases of the Prostate RONALD M. TOWNSEND, M.D. Department of Laboratory Medicine,
More informationChapter 3. Neoplasms. Copyright 2015 Cengage Learning.
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationSEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationP rare and, therefore, their histopathologic
PROSTATIC ADENOCARCINOMA OF DUCTAL ORIGIN VOLKER E. DUBE, MD,+ GEORGE M. FARROW, AND LAURENCE F. GREENE, MD+ MD+ Clinical and histopathologic features of prostatic ductal adenocarcinomas have been incompletely
More informationAnaplastic A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.
Oncology Terminology A Adenocarcinoma A cancerous tumor that arises in or resembles glandular tissue. Adjunct agent In cancer therapy, a drug or substance used in addition to the primary therapy. Adjuvant
More informationProstatic Acid Phosphatase: A Potpourri*
Prostatic Acid Phosphatase: A Potpourri* CHARLES W. MONCURE, M.D. Assistant Professor of Pathology, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond,
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationDiagnosis of prostate cancer
Diagnosis of prostate cancer Epidemiology Prostate cancer (PC) is the most common cancer in men and the 2 nd cause of cancer death in the developed world. Incidence with age, reaching 80% at age 80 (at
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationAPPENDIX. Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection
APPENDIX D Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection APPENDIX D: STUDIES OF PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER SCREENING AND EARLY DETECTION: RESEARCH
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationS1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationTHE incidence of cancer of the prostate gland among men who have symptoms
PROSTATE GLAND BIOPSY EUGENE F. POUTASSE, Department of Urology M.D. THE incidence of cancer of the prostate gland among men who have symptoms of bladder neck obstruction is about one out of five. The
More information3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationProstate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)
Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1) Jae Y. Ro, MD, PhD June 7, 2012 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths By Sex, United States,
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationTumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.
Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationAuthor(s) Segawa, Takehiko; Kakehi, Yoshiyuki. Citation 泌尿器科紀要 (1993), 39(6):
Title Primary signet ring cell adenocarci report and literature review Author(s) Segawa, Takehiko; Kakehi, Yoshiyuki Citation 泌尿器科紀要 (1993), 39(6): 565-568 Issue Date 1993-06 URL http://hdl.handle.net/2433/117859
More informationPatent WO2012015904A2 - Biomarkers for prostate cancer and methods using the same -... Page 1 of 35 +You Search Images Maps Play YouTube News Gmail Drive Calendar More wo/2012/015904a2 SIGN IN Patents
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationTumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director
Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationBenefits, Risks, and Costs of Screening
CHAPTER 5 Benefits, Risks, and Costs of Screening his chapter draws from the literature reviewed in the previous three chapters to analyze the impact of a hypothetical prostate cancer screening program
More informationRubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer
Research Article TheScientificWorldJOURNAL (2011) 11, 1560 1567 ISSN 1537-744X; DOI 10.1100/tsw.2011.145 Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer Henry M. Rosevear 1, Andrew J.
More information2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseudocapsule
GENITOURINARY PATHOLOGY Kathleen M. O Toole, M.D. Renal Cell Carcinoma 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow Necrotic Mass Grossly is a Bright
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationDiagnosis, pathology and prognosis including variant pathology
PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationCase Scenario 1. Discharge Summary
Case Scenario 1 Discharge Summary A 69-year-old woman was on vacation and noted that she was becoming jaundiced. Two months prior to leaving on that trip, she had had a workup that included an abdominal
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationWorkup of a Solid Liver Lesion
Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationElevation of Creatine Kinase BB CK in Hospitalized Patients
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 5 Copyright 182, Institute for Clinical Science, Inc. Elevation of Creatine Kinase BB CK in Hospitalized Patients Importance of Distinguishing BB
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationSaira Khan. Chapel Hill Approved by: Andrew F. Olshan. Jeannette T. Bensen. Jianwen Cai. Matthew E. Nielsen. Melissa A.
DIABETES AND PROSTATE CANCER AGGRESSIVENESS AT DIAGNOSIS AND PROGRESSION IN WHITE AMERICANS AND BLACK AMERICANS FROM THE NORTH CAROLINA-LOUISIANA PROSTATE CANCER PROJECT (PCaP) Saira Khan A dissertation
More informationPatient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for
High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...
More informationISSN: Page 1. SSRG International Journal of Medical Science (SSRG-IJMS) volume 2 Issue 6 June 2015
Correlation between Prostate Specific Antigen and Acid Phosphatase with Histopathological Findings in Various Prostatic Pathologies Dr Anusha A.M 1, Dr S.Ranjith 2, Dr P.T Annamala 3 1 Assistant Professor,
More informationQuestions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test
Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationBREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationEssentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis
73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationTHE DILEMMA OF PROSTATE CANcer
ORIGINAL CONTRIBUTION Biological Determinants of Cancer Progression in Men With Prostate Cancer Thomas A. Stamey, MD John E. McNeal, MD Cheryl M. Yemoto Bronislava M. Sigal, PhD Iain M. Johnstone, PhD
More informationCollecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009
Collecting Cancer Data: Prostate NAACCR 2008-2009 Webinar Series June 11, 2009 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview 2008-2009 NAACCR Webinar Series
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More informationProcedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy
Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle
More informationAdvanced Pathophysiology Unit 7: Renal-Urologic Page 1 of 6
Advanced Pathophysiology Unit 7: Renal-Urologic Page 1 of 6 Learning Objectives for this File: 1. Understand how clinical presentation drives the diagnostic workup 2. Recognize how patient education is
More informationCollaborative Staging
Slide 1 Collaborative Staging Site-Specific Instructions Prostate 1 In this presentation, we are going to take a closer look at the collaborative staging data items for the prostate primary site. Because
More informationCase Report New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
Case Reports in Oncological Medicine Volume 2015, Article ID 358572, 5 pages http://dx.doi.org/10.1155/2015/358572 Case Report New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationThe Importance of Prognostic Factors in Advanced Prostate Cancer
The Importance of Prognostic Factors in Advanced Prostate Cancer MarkS. Soloway, MD Three factors were identified in a multivariate analysis of prognostic factors in men with metastatic prostate cancer
More informationR. F. Falkenstern-Ge, 1 S. Bode-Erdmann, 2 G. Ott, 2 M. Wohlleber, 1 and M. Kohlhäufl Introduction. 2. Histology
Case Reports in Oncological Medicine Volume 2013, Article ID 167585, 4 pages http://dx.doi.org/10.1155/2013/167585 Case Report Late Lung Metastasis of a Primary Eccrine Sweat Gland Carcinoma 10 Years after
More informationE levated Prolactin Level in Prostates with Latent Carcinoma
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 17, No. 3 Copyright 1987, Institute for Clinical Science, Inc. E levated Prolactin Level in Prostates with Latent Carcinoma RYUICHI YATANI, M.D.,* ITSUO
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationEndoscopic Ultrasonography Assessment for Ampullary and Bile Duct Malignancy
Diagnostic and Therapeutic Endoscopy, Vol. 3, pp. 35-40 Reprints available directly from the publisher Photocopying permitted by license only (C) 1996 OPA (Overseas Publishers Association) Amsterdam B.V.
More informationDiagnosis and Classification of Prostate Cancer
Patient Information English 32 Diagnosis and Classification of Prostate Cancer The underlined terms are listed in the glossary. prostate biopsy is the only test that can confirm a prostate cancer diagnosis.
More information